Literature DB >> 18437540

ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.

Rebecca S Muraoka-Cook1, Shu-Mang Feng, Karen E Strunk, H Shelton Earp.   

Abstract

The ErbB receptor tyrosine kinase family has often been associated with increased growth of breast epithelial cells, as well as malignant transformation and progression. In contrast, ErbB4/HER4 exhibits unique attributes from a two step proteolytic cleavage which releases an 80 kilodalton, nuclear localizing, tyrosine kinase to a signal transduction mechanism that slows growth and stimulates differentiation of breast cells. This review provides an overview of ErbB4/HER4 in growth and differentiation of the mammary epithelium, including its physiologic role in development, the contrasting growth inhibition/tumor suppression and growth acceleration of distinct ErbB4/HER4 isoforms and a description of the unique cell cycle regulated pattern of nuclear HER4 ubiquitination and destruction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437540      PMCID: PMC3325098          DOI: 10.1007/s10911-008-9080-x

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  83 in total

1.  Expression of heregulin and ErbB/Her receptors in adult chinchilla cochlear and vestibular sensory epithelium.

Authors:  Mei Zhang; Dalian Ding; Richard Salvi
Journal:  Hear Res       Date:  2002-07       Impact factor: 3.208

2.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

Authors:  S COHEN
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

3.  High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.

Authors:  Dalia M Abd El-Rehim; Graham Ball; Sarah E Pinder; Emad Rakha; Claire Paish; John F R Robertson; Douglas Macmillan; Roger W Blamey; Ian O Ellis
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

4.  Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

Authors:  Rebecca S Muraoka-Cook; Laura S Caskey; Melissa A Sandahl; Debra M Hunter; Carty Husted; Karen E Strunk; Carolyn I Sartor; William A Rearick; Wesley McCall; Magdalene K Sgagias; Kenneth H Cowan; H Shelton Earp
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.

Authors:  C K Tang; X Z Concepcion; M Milan; X Gong; E Montgomery; M E Lippman
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma.

Authors:  R Gilbertson; R Hernan; T Pietsch; L Pinto; P Scotting; R Allibone; D Ellison; R Perry; A Pearson; J Lunec
Journal:  Genes Chromosomes Cancer       Date:  2001-07       Impact factor: 5.006

7.  Stat5a is mandatory for adult mammary gland development and lactogenesis.

Authors:  X Liu; G W Robinson; K U Wagner; L Garrett; A Wynshaw-Boris; L Hennighausen
Journal:  Genes Dev       Date:  1997-01-15       Impact factor: 11.361

8.  WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function.

Authors:  Rami I Aqeilan; Valentina Donati; Alexey Palamarchuk; Francesco Trapasso; Mohamed Kaou; Yuri Pekarsky; Marius Sudol; Carlo M Croce
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

9.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

10.  Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

Authors:  Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke
Journal:  Breast Cancer Res       Date:  2004-03-23       Impact factor: 6.466

View more
  47 in total

Review 1.  E3 ubiquitin ligases in ErbB receptor quantity control.

Authors:  Kermit L Carraway
Journal:  Semin Cell Dev Biol       Date:  2010-09-22       Impact factor: 7.727

2.  ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

Authors:  Meghan M Morrison; Katherine Hutchinson; Michelle M Williams; Jamie C Stanford; Justin M Balko; Christian Young; Maria G Kuba; Violeta Sánchez; Andrew J Williams; Donna J Hicks; Carlos L Arteaga; Aleix Prat; Charles M Perou; H Shelton Earp; Suleiman Massarweh; Rebecca S Cook
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 3.  The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Authors:  Benjamin A Mooso; Ruth L Vinall; Maria Mudryj; Stanley A Yap; Ralph W deVere White; Paramita M Ghosh
Journal:  J Urol       Date:  2014-08-23       Impact factor: 7.450

Review 4.  Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.

Authors:  Y-N Wang; H Yamaguchi; J-M Hsu; M-C Hung
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

Review 5.  Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders.

Authors:  Miranda L Fisher; Anu Loukola; Jaakko Kaprio; Jill R Turner
Journal:  Int Rev Neurobiol       Date:  2015-09-16       Impact factor: 3.230

6.  Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1.

Authors:  Nicole Forster; Srinivas Vinod Saladi; Maaike van Bragt; Mary E Sfondouris; Frank E Jones; Zhe Li; Leif W Ellisen
Journal:  Dev Cell       Date:  2014-01-09       Impact factor: 12.270

Review 7.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

8.  Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles.

Authors:  Robert Klopfleisch; Dido Lenze; Michael Hummel; Achim D Gruber
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

9.  Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Authors:  Andrea Sassen; Simone Diermeier-Daucher; Manuela Sieben; Olaf Ortmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff
Journal:  Breast Cancer Res       Date:  2009-07-22       Impact factor: 6.466

10.  The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

Authors:  Y L Chua; Y Ito; J C M Pole; S Newman; S-F Chin; R C Stein; I O Ellis; C Caldas; M J O'Hare; A Murrell; P A W Edwards
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.